Staccato Alprazolam Abuse Liability

Summary

Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and Staccato Placebo.

Conditions

• Abuse Liability of Staccato Alprazolam

Interventions

DRUG

Inhaled placebo + oral placebo

Inhaled Staccato placebo + oral placebo

DRUG

Inhaled alprazolam 0.5 mg

Inhaled Staccato alprazolam 0.5 mg + oral placebo

DRUG

Inhaled alprazolam 1 mg

Inhaled Staccato alprazolam 1 mg + oral placebo

DRUG

Inhaled alprazolam 2 mg

Inhaled Staccato alprazolam 2 mg + oral placebo

DRUG

Oral alprazolam 1 mg

Oral alprazolam 1 mg + Inhaled placebo

DRUG

Oral alprazolam 2 mg

Oral alprazolam 2 mg + Inhaled placebo

DRUG

Oral alprazolam 4 m

Oral alprazolam 4 mg + Inhaled placebo

DRUG

Oral alprazolam 2 mg qualifying session

Qualifying session (2 mg oral alprazolam)

DRUG

Oral placebo qualifying session

Qualifying control session (oral placebo)

Sponsors & Collaborators

• Nova Pneuma Inc.

  lead INDUSTRY

Principal Investigators

• Roland R Griffiths, PhD · Johns Hopkins University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2008-01-31

Primary Completion

2009-01-31

Completion

2009-01-31

FDA Drug

Yes

Countries

• United States

Study Locations